Title:  People and idea are LegoChem’s key competitiveness

Publication: Daejon ilbo / Dae-Ho Kim

Date: 15 Oct 2014

URL: link to website (contents in Korean)

Summary

·         Dr. Yong-Zu Kim, CEO and President of LegoChem Biosciences has been a renowned expert in research and development of drugs both domestically and internationally.

·         He is one of the few experts in Korea with experience ranging from the discovery stage through development to US FDA approval.

·         LegoChem’s LegoChemistry significantly reduces the time periods from drug hit to candidate, and its Gate Decision System ensures that global R&D pipelines of drug candidates meet global standards and regulations.

·         Dr. Kim emphasized that LegoChem will grow to a bio venture company representing local economies, by generating profits from out-licensing its technologies to global pharmaceutical companies.

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).